Posted: Thursday, April 1, 2021
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses the latest data on selecting treatment for patients with relapsed or refractory CLL/SLL, the factors to consider, and recommendations on following those with minimal residual disease.